Regulatory B cells in anti-tumor immunity
Advances in understanding of the immune microenvironment have highlighted the role of immunosuppressive T cell, myeloid, dendritic and monocytic sub-populations in inhibition of the anti-tumor immune response. The role of B cells in modulating the immune response to solid tumors as well as lymphoid...
Uložené v:
| Vydané v: | International immunology Ročník 27; číslo 10; s. 521 |
|---|---|
| Hlavní autori: | , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
01.10.2015
|
| Predmet: | |
| ISSN: | 1460-2377, 1460-2377 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Advances in understanding of the immune microenvironment have highlighted the role of immunosuppressive T cell, myeloid, dendritic and monocytic sub-populations in inhibition of the anti-tumor immune response. The role of B cells in modulating the immune response to solid tumors as well as lymphoid malignancies is less well understood. Murine models of autoimmune disease have defined B regulatory cell (Breg) subsets with immune suppressive activity, including B cell subsets that express IL-10, and transforming growth factor-β, which can facilitate T regulatory cell recruitment and expansion. Multiple murine tumor models point to the existence of similar immune suppressive B cell sub-populations that can migrate into tumor deposits and acquire an immune suppressive phenotype, which then leads to attenuation of the local anti-tumor immune response. Other murine models of viral or chemically induced skin carcinogenesis have identified a pivotal role for B cells in promoting inflammation and carcinogenesis. While many human solid tumors demonstrate significant B cell infiltration and/or tertiary lymphoid structure formation, the functional properties of tumor-infiltrating B cells and their effects on immunity are poorly understood. Recent successes in early Phase I/II trials using anti-checkpoint inhibitor antibodies such as nivolumab or pidilizumab directed against PD-1 in the setting of Hodgkin's and non-Hodgkin's lymphomas validate the therapeutic utility of reversing B cell-mediated immune suppression. Further studies to define Breg subsets, and mechanisms of suppression, may provide new avenues for modulation of the immune response and meaningful therapeutic intervention in both lymphoid and solid tumors. |
|---|---|
| AbstractList | Advances in understanding of the immune microenvironment have highlighted the role of immunosuppressive T cell, myeloid, dendritic and monocytic sub-populations in inhibition of the anti-tumor immune response. The role of B cells in modulating the immune response to solid tumors as well as lymphoid malignancies is less well understood. Murine models of autoimmune disease have defined B regulatory cell (Breg) subsets with immune suppressive activity, including B cell subsets that express IL-10, and transforming growth factor-β, which can facilitate T regulatory cell recruitment and expansion. Multiple murine tumor models point to the existence of similar immune suppressive B cell sub-populations that can migrate into tumor deposits and acquire an immune suppressive phenotype, which then leads to attenuation of the local anti-tumor immune response. Other murine models of viral or chemically induced skin carcinogenesis have identified a pivotal role for B cells in promoting inflammation and carcinogenesis. While many human solid tumors demonstrate significant B cell infiltration and/or tertiary lymphoid structure formation, the functional properties of tumor-infiltrating B cells and their effects on immunity are poorly understood. Recent successes in early Phase I/II trials using anti-checkpoint inhibitor antibodies such as nivolumab or pidilizumab directed against PD-1 in the setting of Hodgkin's and non-Hodgkin's lymphomas validate the therapeutic utility of reversing B cell-mediated immune suppression. Further studies to define Breg subsets, and mechanisms of suppression, may provide new avenues for modulation of the immune response and meaningful therapeutic intervention in both lymphoid and solid tumors. Advances in understanding of the immune microenvironment have highlighted the role of immunosuppressive T cell, myeloid, dendritic and monocytic sub-populations in inhibition of the anti-tumor immune response. The role of B cells in modulating the immune response to solid tumors as well as lymphoid malignancies is less well understood. Murine models of autoimmune disease have defined B regulatory cell (Breg) subsets with immune suppressive activity, including B cell subsets that express IL-10, and transforming growth factor-β, which can facilitate T regulatory cell recruitment and expansion. Multiple murine tumor models point to the existence of similar immune suppressive B cell sub-populations that can migrate into tumor deposits and acquire an immune suppressive phenotype, which then leads to attenuation of the local anti-tumor immune response. Other murine models of viral or chemically induced skin carcinogenesis have identified a pivotal role for B cells in promoting inflammation and carcinogenesis. While many human solid tumors demonstrate significant B cell infiltration and/or tertiary lymphoid structure formation, the functional properties of tumor-infiltrating B cells and their effects on immunity are poorly understood. Recent successes in early Phase I/II trials using anti-checkpoint inhibitor antibodies such as nivolumab or pidilizumab directed against PD-1 in the setting of Hodgkin's and non-Hodgkin's lymphomas validate the therapeutic utility of reversing B cell-mediated immune suppression. Further studies to define Breg subsets, and mechanisms of suppression, may provide new avenues for modulation of the immune response and meaningful therapeutic intervention in both lymphoid and solid tumors.Advances in understanding of the immune microenvironment have highlighted the role of immunosuppressive T cell, myeloid, dendritic and monocytic sub-populations in inhibition of the anti-tumor immune response. The role of B cells in modulating the immune response to solid tumors as well as lymphoid malignancies is less well understood. Murine models of autoimmune disease have defined B regulatory cell (Breg) subsets with immune suppressive activity, including B cell subsets that express IL-10, and transforming growth factor-β, which can facilitate T regulatory cell recruitment and expansion. Multiple murine tumor models point to the existence of similar immune suppressive B cell sub-populations that can migrate into tumor deposits and acquire an immune suppressive phenotype, which then leads to attenuation of the local anti-tumor immune response. Other murine models of viral or chemically induced skin carcinogenesis have identified a pivotal role for B cells in promoting inflammation and carcinogenesis. While many human solid tumors demonstrate significant B cell infiltration and/or tertiary lymphoid structure formation, the functional properties of tumor-infiltrating B cells and their effects on immunity are poorly understood. Recent successes in early Phase I/II trials using anti-checkpoint inhibitor antibodies such as nivolumab or pidilizumab directed against PD-1 in the setting of Hodgkin's and non-Hodgkin's lymphomas validate the therapeutic utility of reversing B cell-mediated immune suppression. Further studies to define Breg subsets, and mechanisms of suppression, may provide new avenues for modulation of the immune response and meaningful therapeutic intervention in both lymphoid and solid tumors. |
| Author | Rosenblatt, Joseph D Zhang, Yu Gallastegui, Nicolas |
| Author_xml | – sequence: 1 givenname: Yu surname: Zhang fullname: Zhang, Yu organization: Division of Hematology/Oncology, Department of Medicine, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA – sequence: 2 givenname: Nicolas surname: Gallastegui fullname: Gallastegui, Nicolas organization: Division of Hematology/Oncology, Department of Medicine, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA – sequence: 3 givenname: Joseph D surname: Rosenblatt fullname: Rosenblatt, Joseph D email: jrosenblatt@med.miami.edu organization: Division of Hematology/Oncology, Department of Medicine, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA jrosenblatt@med.miami.edu |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25999597$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj0tLxDAYRYOMOA9dupUudVEnj6ZJljr4ggFBdF3S5KtEmnRsGpn-eyuO4OrexeFw7xLNQhcAoXOCrwlWbO3C4Lxf2_0XZsURWpCixDllQsz-9TlaxviBMWZUsRM0p1wpxZVYoKsXeE-tHrp-zG4zA20bMxcyPVnzIfmuzyZ7Cm4YT9Fxo9sIZ4dcobf7u9fNY759fnja3Gxzw5Qc8lo3RlAwqjSKyIITbY0lYDVwBo2RmnJZU2GlNESBwFgXllLV8ImQDRV0hS5_vbu--0wQh8q7-DNMB-hSrIggkjEqVTmhFwc01R5steud1_1Y_d2j3y9VVH4 |
| CitedBy_id | crossref_primary_10_1016_j_intimp_2023_110586 crossref_primary_10_3389_fimmu_2022_867902 crossref_primary_10_1021_acsbiomaterials_4c01725 crossref_primary_10_3389_fonc_2022_956348 crossref_primary_10_1080_2162402X_2016_1204505 crossref_primary_10_31146_1682_8658_ecg_202_6_76_82 crossref_primary_10_3390_genes13060951 crossref_primary_10_1016_j_csbj_2022_08_057 crossref_primary_10_1016_j_intimp_2025_115310 crossref_primary_10_4049_jimmunol_1701069 crossref_primary_10_1007_s10549_020_05548_y crossref_primary_10_1080_08916934_2019_1697690 crossref_primary_10_1016_j_cyto_2017_10_011 crossref_primary_10_3390_ijms22041957 crossref_primary_10_1002_cbf_3270 crossref_primary_10_1186_s40425_018_0450_7 crossref_primary_10_1002_JLB_5RU0518_199R crossref_primary_10_2147_OTT_S286274 crossref_primary_10_1016_j_humimm_2022_01_014 crossref_primary_10_1038_nrd_2016_193 crossref_primary_10_1111_1346_8138_15272 crossref_primary_10_1007_s00335_018_9778_z crossref_primary_10_1038_s41556_024_01508_6 crossref_primary_10_1177_1010428317705747 crossref_primary_10_3389_fmolb_2024_1490745 crossref_primary_10_1136_jitc_2021_002475 crossref_primary_10_1016_j_molimm_2020_01_008 crossref_primary_10_2174_0929867327666200128105459 crossref_primary_10_1080_2162402X_2020_1860586 crossref_primary_10_3389_fimmu_2024_1519034 crossref_primary_10_1186_s12957_021_02272_9 crossref_primary_10_3389_fimmu_2020_582657 crossref_primary_10_1007_s00106_018_0494_5 crossref_primary_10_1080_2162402X_2017_1336593 crossref_primary_10_1016_j_canlet_2023_216182 crossref_primary_10_53941_hm_2025_100023 crossref_primary_10_3390_cancers14071681 crossref_primary_10_1038_s41392_021_00658_5 crossref_primary_10_1159_000500890 crossref_primary_10_1080_2162402X_2017_1294296 crossref_primary_10_1186_s13046_020_01727_3 crossref_primary_10_1016_j_intimp_2019_106111 crossref_primary_10_3389_fimmu_2021_690105 crossref_primary_10_1016_j_clim_2017_04_011 crossref_primary_10_3390_cells9071664 crossref_primary_10_1007_s11523_017_0481_x crossref_primary_10_1080_08916934_2022_2093862 crossref_primary_10_1080_13543784_2020_1814253 crossref_primary_10_3892_ol_2021_13097 crossref_primary_10_3389_fimmu_2020_594841 crossref_primary_10_3389_fimmu_2020_622442 crossref_primary_10_1038_srep32754 crossref_primary_10_1093_intimm_dxz068 crossref_primary_10_1016_j_jmb_2020_07_019 crossref_primary_10_1111_1759_7714_15380 crossref_primary_10_1172_JCI85113 crossref_primary_10_3390_ijms21093329 crossref_primary_10_1016_j_cyto_2019_03_006 crossref_primary_10_3389_fimmu_2020_558757 crossref_primary_10_3389_fimmu_2021_639636 crossref_primary_10_1158_2326_6066_CIR_21_1073 crossref_primary_10_1080_2162402X_2018_1554968 crossref_primary_10_1158_2159_8290_CD_16_0100 crossref_primary_10_1111_vco_12556 crossref_primary_10_3390_cancers15041015 crossref_primary_10_3389_fimmu_2021_670324 crossref_primary_10_3389_fonc_2021_738477 crossref_primary_10_1016_j_drudis_2016_04_010 crossref_primary_10_1158_2159_8290_CD_16_0307 crossref_primary_10_25259_IJDVL_1003_2021 crossref_primary_10_1016_j_jconrel_2019_07_039 crossref_primary_10_1038_s41416_023_02321_y crossref_primary_10_1111_sji_12830 crossref_primary_10_1093_annonc_mdy326 crossref_primary_10_1038_s42003_020_01391_5 crossref_primary_10_3390_ijms23095287 crossref_primary_10_1016_j_semcdb_2019_12_010 crossref_primary_10_4103_jomfp_JOMFP_121_20 crossref_primary_10_1111_his_13695 crossref_primary_10_3390_ijms21218238 crossref_primary_10_1016_j_jaci_2016_07_006 crossref_primary_10_1038_s41423_018_0027_x crossref_primary_10_3389_fimmu_2020_00020 crossref_primary_10_1186_s12935_021_02004_9 crossref_primary_10_1073_pnas_1604752113 |
| ContentType | Journal Article |
| Copyright | The Japanese Society for Immunology. 2015. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| Copyright_xml | – notice: The Japanese Society for Immunology. 2015. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/intimm/dxv034 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1460-2377 |
| ExternalDocumentID | 25999597 |
| Genre | Journal Article Review |
| GroupedDBID | --- -E4 .2P .55 .GJ .I3 .ZR 0R~ 18M 1TH 29J 2WC 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 70D A8Z AABZA AACZT AAIMJ AAJKP AAJQQ AAMDB AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAVLN AAWDT ABDFA ABEJV ABEUO ABGNP ABIME ABIXL ABJNI ABKDP ABMNT ABNGD ABNHQ ABNKS ABOCM ABPIB ABPQP ABPTD ABQLI ABQNK ABSMQ ABVGC ABWST ABXVV ABXZS ABZBJ ABZEO ACFRR ACGFO ACGFS ACIWK ACPQN ACPRK ACUFI ACUKT ACUTJ ACUTO ACVCV ACYHN ACZBC ADBBV ADEYI ADEZT ADFTL ADGKP ADGZP ADHKW ADHZD ADIPN ADMTO ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZTZ ADZXQ AEGPL AEGXH AEHUL AEJOX AEKPW AEKSI AELWJ AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFNX AFFQV AFFZL AFGWE AFIYH AFOFC AFRAH AFSHK AFXAL AFYAG AGINJ AGKEF AGKRT AGMDO AGORE AGQPQ AGQXC AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AI. AIAGR AIJHB AJBYB AJDVS AJEEA AJNCP AKHUL AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX ANFBD APIBT APJGH APWMN AQDSO AQKUS ARIXL ASAOO ASPBG ATDFG ATGXG ATTQO AVNTJ AVWKF AXUDD AYOIW AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BQDIO BSWAC BTRTY BVRKM BZKNY C1A C45 CAG CDBKE CGR COF CS3 CUY CVF CXTWN CZ4 DAKXR DFGAJ DIK DILTD DU5 D~K E3Z EBD EBS ECM EE~ EIF EIHJH EJD ELUNK EMOBN ENERS F5P F9B FECEO FEDTE FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HVGLF HW0 HZ~ IH2 IOX J21 J8S JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN M-Z MBLQV MBTAY MHKGH N9A NGC NLBLG NOMLY NOYVH NPM NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OBC OBFPC OBOKY OBS OCZFY ODMLO OEB OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD R44 RD5 RIG RNI ROL ROX ROZ RUSNO RW1 RXO RZF RZO SV3 TCN TEORI TJX TLC TMA TR2 UDS VH1 W8F WOQ X7H X7M Y6R YAYTL YHZ YKOAZ YXANX ZKX ~91 7X8 ESTFP |
| ID | FETCH-LOGICAL-c398t-bafc72ec96c918451adcd1edae53efc8a258b27d88c19e700a4d229f5dae8f272 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 99 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000364767100008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1460-2377 |
| IngestDate | Wed Oct 01 13:04:24 EDT 2025 Mon Jul 21 05:53:59 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | B regulatory cells TGF-β anti-tumor immunity IL-10 |
| Language | English |
| License | The Japanese Society for Immunology. 2015. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c398t-bafc72ec96c918451adcd1edae53efc8a258b27d88c19e700a4d229f5dae8f272 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://academic.oup.com/intimm/article-pdf/27/10/521/45027560/intimm_27_10_521.pdf |
| PMID | 25999597 |
| PQID | 1718332896 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1718332896 pubmed_primary_25999597 |
| PublicationCentury | 2000 |
| PublicationDate | 2015-10-01 |
| PublicationDateYYYYMMDD | 2015-10-01 |
| PublicationDate_xml | – month: 10 year: 2015 text: 2015-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | International immunology |
| PublicationTitleAlternate | Int Immunol |
| PublicationYear | 2015 |
| SSID | ssj0003293 |
| Score | 2.4678648 |
| SecondaryResourceType | review_article |
| Snippet | Advances in understanding of the immune microenvironment have highlighted the role of immunosuppressive T cell, myeloid, dendritic and monocytic... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 521 |
| SubjectTerms | Animals Autoimmune Diseases - genetics Autoimmune Diseases - immunology Autoimmune Diseases - pathology B-Lymphocytes, Regulatory - immunology B-Lymphocytes, Regulatory - pathology Cell Lineage - immunology Clinical Trials as Topic Disease Models, Animal Gene Expression Regulation, Neoplastic - immunology Hodgkin Disease - genetics Hodgkin Disease - immunology Hodgkin Disease - pathology Humans Immune Tolerance Interleukin-10 - genetics Interleukin-10 - immunology Lymphoma, Non-Hodgkin - genetics Lymphoma, Non-Hodgkin - immunology Lymphoma, Non-Hodgkin - pathology Mice Signal Transduction T-Lymphocytes, Regulatory - immunology T-Lymphocytes, Regulatory - pathology Transforming Growth Factor beta - genetics Transforming Growth Factor beta - immunology Tumor Microenvironment - immunology |
| Title | Regulatory B cells in anti-tumor immunity |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/25999597 https://www.proquest.com/docview/1718332896 |
| Volume | 27 |
| WOSCitedRecordID | wos000364767100008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAAmLhUV7lpSCxMFgkdhLbEwJExdKqQiB1ixw_pAxNSpNW9N9zTlJ1QkJiyeRE1vly_u7O_j6E7kKrFSCFFGtuFQ5jcGPYFkJMIy7C0MggYKoWm2DDIR-PxagtuJXtscpVTKwDtS6Uq5E_BBBEKYX0IH6cfmGnGuW6q62ExibqUIAyzqvZeM0WTklNugvBwMeEMtZybEIS_5DlVTaBr38vfKeZ_Bu6rHeZ_sF_53eI9lt86T01DnGENkzeRTuN4uSyi3YHbS_9GN2_NzL0xWzpPXuugF96We6BpTNczSfFzMvquyPV8gR99l8_Xt5wK5yAFRW8wqm0ihGjRKwEGD4KpFY6MFqaiBqruCQRTwnTnKtAGOb7MtSECBvBCG4JI6doKy9yc448bYUGlJgSE5NQApwJVGQ4UXV7jaVpD92uzJGAY7rJytwU8zJZG6SHzhqbJtOGQSOBnMvxnLGLP7x9ifYApETNAbor1LHwW5prtK0WVVbObuoVh-dwNPgBdF21_w |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Regulatory+B+cells+in+anti-tumor+immunity&rft.jtitle=International+immunology&rft.au=Zhang%2C+Yu&rft.au=Gallastegui%2C+Nicolas&rft.au=Rosenblatt%2C+Joseph+D&rft.date=2015-10-01&rft.issn=1460-2377&rft.eissn=1460-2377&rft.volume=27&rft.issue=10&rft.spage=521&rft_id=info:doi/10.1093%2Fintimm%2Fdxv034&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1460-2377&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1460-2377&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1460-2377&client=summon |